EnliTISA is a clinical stage biopharmaceutical company focused on developing novel therapeutics with a primary focus on inflammatory and fibrotic conditions with unmet medical needs. EnliTISA, based in Shanghai, China, was founded by Chinese and Swedish team members in 2021, and is focusing on anti-inflammatory and anti-fibrosis multi-innovative drug development. The Chinese-Swedish team collaborates on pre-clinical and clinical development of drugs in China, Europe and the US. All projects in the pipeline are based on the inventions made by the EnliTISA team. By now, twelve patent applications have been filed and two patents in China and one in US have been granted.
International invention patents
R & D Innovation
Potter Clarkson Intellectual Property Office, UK
· Has cooperated with the company for 5 and a half years, responsible for the company's intellectual property strategy construction and international PCT application, completed 12 international invention patent applications, 2 Chinese patent authorizations, and 1 US patent authorization. IP due diligence and negotiation to support Chinese and overseas transactions · Supported over 70 clients in IP due diligence and negotiation of intercontinental licensing transactions
The world's leading original innovative
drug enterprise for inflammation and injury
The world's leading original innovative drug enterprise for inflammation and injury
The Phase II clinical trial of TISA-818-Inj for the treatment of acute respiratory distress syndrome (ARDS) recently completed first patient first visit (FPFV), which was led by Professor Zhan Qingyuan of the China-Japan Friendship Hospital and sponsored by EnliTISA (Shang Hai) Pharmaceutical Co., Ltd (Abbreviated as EnliTISA).